Cargando…
The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy
PURPOSE: To assess the safety and usefulness of neutron brachytherapy (NBT) as an adjuvant in the treatment of patients with gastroesophageal junction adenocarcinoma (GEJAC) with external beam radiation (EBRT), with or without chemotherapy. METHODS AND MATERIALS: In total, 197 patients with localize...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016616/ https://www.ncbi.nlm.nih.gov/pubmed/24774780 http://dx.doi.org/10.1186/1748-717X-9-99 |
_version_ | 1782315533507493888 |
---|---|
author | Wang, Qifeng Li, Tao Liu, Huiming Jia, Xitang Liu, Bo Wan, Xin Lang, Jinyi |
author_facet | Wang, Qifeng Li, Tao Liu, Huiming Jia, Xitang Liu, Bo Wan, Xin Lang, Jinyi |
author_sort | Wang, Qifeng |
collection | PubMed |
description | PURPOSE: To assess the safety and usefulness of neutron brachytherapy (NBT) as an adjuvant in the treatment of patients with gastroesophageal junction adenocarcinoma (GEJAC) with external beam radiation (EBRT), with or without chemotherapy. METHODS AND MATERIALS: In total, 197 patients with localized, advanced GEJAC received EBRT and NBT with or without chemotherapy. Radiotherapy consisted of external irradiation to a total dose of 40–54 Gy (median 50 Gy) and brachytherapy to 8–25 Gy (median 20 Gy) in two to five fractions. In total, 88 patients received chemotherapy that consisted of two cycles of a regimen with CDDP and 5FU from days l-4. The cycles were administered on days 1 and 29. MMC was given alone in bolus injection on day 1 each week. The cycles were administered on days 1, 8, 15 and 22. RESULTS: The duration of follow-up ranged from six to 106 months (median 30.4 months). The median survival time for the 197 patients was 13.3 months, and the one, two, three- and five-year rates for overall survival were 57.1%, 35.1%, 23.0% and 9.2%, respectively. For acute toxicity, no incidences of fistula and massive bleeding were observed during this treatment period. In total, 159 (80.7%) patients developed Grade 2 hematologic toxicity and 146 (74.1%) patients developed Grade ≥ 2 esophagitis. The median times of incidence of fistula and bleeding were 9.5 (3–27.3) months and 12.7 (5–43.4) months, respectively. The incidence of severe, late complications was related to higher NBT dose/f (20–25 Gy/5 F) and higher total dose(≥70 Gy). In total, 75.2% of the patients resumed normal swallowing and 2.0% had some residual dysphagia (non-malignant) requiring intermittent dilatation. CONCLUSION: A combination of EBRT and NBT with the balloon type applicator was feasible and well tolerated. Better local-regional control and overall survival cannot achieved by a higher dose, and in contrast, a higher dose caused more severe esophageal injury. |
format | Online Article Text |
id | pubmed-4016616 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40166162014-05-11 The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy Wang, Qifeng Li, Tao Liu, Huiming Jia, Xitang Liu, Bo Wan, Xin Lang, Jinyi Radiat Oncol Research PURPOSE: To assess the safety and usefulness of neutron brachytherapy (NBT) as an adjuvant in the treatment of patients with gastroesophageal junction adenocarcinoma (GEJAC) with external beam radiation (EBRT), with or without chemotherapy. METHODS AND MATERIALS: In total, 197 patients with localized, advanced GEJAC received EBRT and NBT with or without chemotherapy. Radiotherapy consisted of external irradiation to a total dose of 40–54 Gy (median 50 Gy) and brachytherapy to 8–25 Gy (median 20 Gy) in two to five fractions. In total, 88 patients received chemotherapy that consisted of two cycles of a regimen with CDDP and 5FU from days l-4. The cycles were administered on days 1 and 29. MMC was given alone in bolus injection on day 1 each week. The cycles were administered on days 1, 8, 15 and 22. RESULTS: The duration of follow-up ranged from six to 106 months (median 30.4 months). The median survival time for the 197 patients was 13.3 months, and the one, two, three- and five-year rates for overall survival were 57.1%, 35.1%, 23.0% and 9.2%, respectively. For acute toxicity, no incidences of fistula and massive bleeding were observed during this treatment period. In total, 159 (80.7%) patients developed Grade 2 hematologic toxicity and 146 (74.1%) patients developed Grade ≥ 2 esophagitis. The median times of incidence of fistula and bleeding were 9.5 (3–27.3) months and 12.7 (5–43.4) months, respectively. The incidence of severe, late complications was related to higher NBT dose/f (20–25 Gy/5 F) and higher total dose(≥70 Gy). In total, 75.2% of the patients resumed normal swallowing and 2.0% had some residual dysphagia (non-malignant) requiring intermittent dilatation. CONCLUSION: A combination of EBRT and NBT with the balloon type applicator was feasible and well tolerated. Better local-regional control and overall survival cannot achieved by a higher dose, and in contrast, a higher dose caused more severe esophageal injury. BioMed Central 2014-04-29 /pmc/articles/PMC4016616/ /pubmed/24774780 http://dx.doi.org/10.1186/1748-717X-9-99 Text en Copyright © 2014 Wang et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
spellingShingle | Research Wang, Qifeng Li, Tao Liu, Huiming Jia, Xitang Liu, Bo Wan, Xin Lang, Jinyi The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy |
title | The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy |
title_full | The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy |
title_fullStr | The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy |
title_full_unstemmed | The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy |
title_short | The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy |
title_sort | safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016616/ https://www.ncbi.nlm.nih.gov/pubmed/24774780 http://dx.doi.org/10.1186/1748-717X-9-99 |
work_keys_str_mv | AT wangqifeng thesafetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy AT litao thesafetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy AT liuhuiming thesafetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy AT jiaxitang thesafetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy AT liubo thesafetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy AT wanxin thesafetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy AT langjinyi thesafetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy AT wangqifeng safetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy AT litao safetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy AT liuhuiming safetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy AT jiaxitang safetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy AT liubo safetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy AT wanxin safetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy AT langjinyi safetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy |